Non classé
Rising Tide Foundation for Clinical Cancer Research: Empowering Patient-Centred Innovations
The Rising Tide Foundation for Clinical Cancer Research (RTFCCR) is a non-profit, charitable organisation founded in 2010 in Schaffhausen, Switzerl...
EU Roundtable Calls for Urgent Action on Disease-Related Malnutrition in Cancer Care
Brussels, February 5, 2025 – The European Parliament recently hosted a crucial roundtable discussion on “Advancing Optimal Nutritional Care: Ad...
DiCE Advocates for Awareness at PANCAID Stakeholder Event
On 15 January 2025, DiCE actively participated in the PANCAID Stakeholder Event at the European Parliament in Brussels, organised by Pancreatic Can...
IMPROVE-2 Trial: A New Treatment Approach for mCRC
The IMPROVE-2 trial is exploring a new way to treat metastatic colorectal cancer (mCRC) by comparing intermittent versus continuous use of Panitumu...
READI Project Officially Launched: Pioneering Diversity and Inclusion in Clinical Studies
On January 16, 2025, the groundbreaking READI project—Research in Europe and Diversity Inclusion—officially launched. Funded by the Horizon Eur...
ESMO Expands Globally with New Patient Advocates Working Group
ESMO is proud to announce the launch of its newly globalised Patient Advocates Working Group (PAWG), now led by Zorana Maravic as Chair. This miles...
Empowering Cancer Patients: SmartCARE Showcase Event
The SmartCARE Showcase Event, organised by the European Cancer Organisation, brought together patient advocates, clinicians, and IT experts to intr...
Advancing Rare Cancer Care: DiCE at the EURACAN Board Meeting
On the 7th and the 8th of November, Laura Urena from Digestive Cancers Europe (DiCE) and a member of EURACAN Patient Advocacy Group (EPAG), partici...
United Against Cancer: Driving Policy and Advocacy at the European Cancer Summit 2024
This event explored innovative strategies to address inequalities and advance cancer care across Europe, aligning closely with Digestive Cancers Eu...
Tevimbra (tislelizumab) Receives New European Recommendations for Oesophageal and Gastric Cancer
Tevimbra (tislelizumab) receives CHMP recommendations for treating PD-L1-positive oesophageal squamous cell carcinoma and gastric/gastroesophageal ...
